Center of discussion ‘cell and gene therapy’

Image Credit: CSL

Announcement 

As the annual event in Phoenix witnessed, industry leaders discussed that cell and gene therapy remained a constant breath in a state of flux, along with regulatory contributions and M&A activity, indicating momentum. At the same time, marketization challenges have consistently drawn vast investor interest. The cell and gene therapy’s pinnacle event concur the signal of recovery for investment in the area, which reflects signs of financial strife. This will create an overall clear picture that would successfully amaze investors in any way, as the company wants to portray.

Big pharma’s strategic and bold moves

This year, big pharma has shown active interest in the M&A front in cell and gene therapy (CGT). For example, AbbVie invested $2.1 billion in Capstan Therapeutics' novel CAR T therapies, Eli Lilly invested $1.3 billion in gene editing for Verve Therapeutics, whereas AstraZeneca completed the purchase of cell therapy leader esobiotech at around $1 billion. This positive change in the companies is due to their struggle to secure sufficient capital to accelerate their assets. This proves as a thoughtful investment for a profitable future.

For example, in the first of the year, the early gene therapy darling, the bluebird, was pushed into a go-private buyout with two leading investment firms that confirmed the biotech at a worth $50 million after its failure at commercial performance in the market of its three approved products. Last week, Takeda waved goodbye to the cell therapy space as it updated its portfolio lineup as per priority.  These circumstances and unpredictable results have moved the companies and their investors to rethink the strategy for real.

This will be a major topic of the discussion at the meeting on the mesa. The meeting will take place in Phoenix, Arizona, from October 6 to 8, with various presentations focusing on secure investment. Alongside, discovering new ways and strategies to marketize products successfully. The vice president of global communications and investor relations at the Alliance of Regenerative Medicine (ARM), the organizer of the meeting on the mesa, Stephen Majors, stated that the space is not in urgent need as continuously portrayed.

Further, he added, “I think the key sentiments regarding the sector have turned out to be negative and don’t align with the current situation. That sentiment has not really been addressed as it should be, considering the best things happened to date.”